Dr. Tam Discusses the DUO Trial for CLL

Constantine S. Tam, MD
Published: Wednesday, Jan 31, 2018



Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the randomized phase III DUO trial of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The phase III DUO trial investigated duvelisib, a PI3-kinase inhibitor, with the standard ofatumumab. Results showed that duvelisib was superior to ofatumumab in terms of progression-free survival (PFS). Median PFS was 13.3 months for duvelisib compared with 9.9 months in the ofatumumab arm. The drug is likely headed for an application for registration, says Tam.

This study randomized 319 patients with CLL/SLL in a 1:1 ratio to duvelisib at 25 mg twice daily until disease progression or unacceptable toxicity, or ofatumumab at 300 mg on day 1, followed by 7 weekly infusions and 4 monthly infusions of 200 mg. Duvelisib reduced the risk of death by 46%.
 


Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses the randomized phase III DUO trial of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The phase III DUO trial investigated duvelisib, a PI3-kinase inhibitor, with the standard ofatumumab. Results showed that duvelisib was superior to ofatumumab in terms of progression-free survival (PFS). Median PFS was 13.3 months for duvelisib compared with 9.9 months in the ofatumumab arm. The drug is likely headed for an application for registration, says Tam.

This study randomized 319 patients with CLL/SLL in a 1:1 ratio to duvelisib at 25 mg twice daily until disease progression or unacceptable toxicity, or ofatumumab at 300 mg on day 1, followed by 7 weekly infusions and 4 monthly infusions of 200 mg. Duvelisib reduced the risk of death by 46%.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x